Biogen Inc. at Morgan Stanley Global Healthcare Conference Transcript
All right. Great. Good morning, everyone. Thanks for joining us. I'm Terence Flynn, Morgan Stanley's US Biopharma Analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Very pleased to be hosting Biogen this morning. Joining us from the company is Chris Viehbacher, the company's President and CEO. Thanks so much, Chris, for joining us on a Monday morning here in Times Square, but really appreciate the time.
Questions & Answers
I just thought we'd maybe start big picture here. The company has been very active -- kind of reshaping the business over -- under your tenure over the last several years. And one area you've been pretty active on is the business development front, including the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
